| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002009704A3 Pharmaceutical composition for transdermal delivery of befloxatone |
| 06/27/2002 | WO2002008231A3 Biologically active macrolides, compositions, and uses thereof |
| 06/27/2002 | WO2001087280A3 Means for treating attacks of auto-immune diseases |
| 06/27/2002 | WO2001080857A9 Zolpidem hemitartrate |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001070978A3 Polypeptides and nucleic acids encoding same |
| 06/27/2002 | WO2001054680A3 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/27/2002 | WO2001053257A3 Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2002 | WO2001050134A3 Methods of detection of amyloidogenic proteins |
| 06/27/2002 | WO2000056350A9 Methods of use of beta 1-integrin inhibitors |
| 06/27/2002 | WO2000056348A9 Inflammatory mediation obtained from atractylodes lancea |
| 06/27/2002 | US20020083477 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves |
| 06/27/2002 | US20020082408 GSK3 polypeptides |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082304 Containing combination inhibitor, combination inhibitor which acts both to interfere with the isolation of sympathomimetic amine from the composition and to interfere with conversion of sympathomimetic amine to another drug |
| 06/27/2002 | US20020082301 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 06/27/2002 | US20020082300 1-((5-(2-(5-tert-Butyl-2-methoxybenzamido)ethyl)-2-methoxyphen yl)- sulfonyl)-3-methylthiourea and propanolol for example |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082285 Method for preventing or treating pain by administering an endothelin antagonist |
| 06/27/2002 | US20020082283 Increasing the function of the N-methylaspartic acid (NMDA) receptor without the inherent side-effects associated with modulation of the glutamate binding site |
| 06/27/2002 | US20020082279 Topical mixture of a carrier, essential oil, and a conventional dermatologic active ingredient |
| 06/27/2002 | US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 06/27/2002 | US20020082276 Quinoline derivatives as anti-inflammatory agents |
| 06/27/2002 | US20020082273 Administering a chelator specific for copper (such as bathocuproine) and clioquinol to prevents formation of and/or induce resolubilization of amyloid beta peptide deposits and reduce reactive oxygen species |
| 06/27/2002 | US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082251 Desmethylolanzapine compositions and methods |
| 06/27/2002 | US20020082245 Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
| 06/27/2002 | US20020082242 Compositions and methods of double-targeting virus infections and cancer cells |
| 06/27/2002 | US20020082235 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 06/27/2002 | US20020082222 Treatments for neurogenetic disorders, impulse control disorder, and wound healing |
| 06/27/2002 | US20020082215 Administering to nasal cavity of mammal a pharmaceutical composition comprising therapeutically effective amount of insulin-like growth factor-I or biologically active variant thereof |
| 06/27/2002 | US20020082213 Administering Orphanin FQ or a pharmacologically active derivative thereof in daily dosage of 0.1 nanograms-0.1 milligrams per kilogram body weight |
| 06/27/2002 | US20020082211 Human presenilin variant |
| 06/27/2002 | US20020082205 Human FGF-23 gene and gene expression products |
| 06/27/2002 | US20020082202 Screening methods using ligands of the neutropeptide receptor HFGAN72 |
| 06/27/2002 | US20020081718 Polypeptide, and a dna sequence to which a protein containing the polypetide binds |
| 06/27/2002 | US20020081695 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 06/27/2002 | US20020081659 Nucleic acids, proteins and antibodies |
| 06/27/2002 | US20020081645 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control |
| 06/27/2002 | US20020081607 Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies |
| 06/27/2002 | US20020081300 Administering the combination of anti-glutamic acid decarboxylase (anti-GAD) antibody and anti-insulin antibody in amount effective to treat or prevent diabetes |
| 06/27/2002 | US20020081286 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/27/2002 | US20020081263 Methods for decreasing beta amyloid protein |
| 06/27/2002 | DE10064105A1 Neue Substituierte Imidazotriazinone New Substituted imidazotriazinones |
| 06/27/2002 | CA2714357A1 Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2436699A1 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | CA2433165A1 Methods for reducing chronic stress in mammals |
| 06/27/2002 | CA2433027A1 Nucleic acid-associated proteins |
| 06/27/2002 | CA2433018A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | CA2432879A1 Anti-allergic complex molecules |
| 06/27/2002 | CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | CA2432638A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | CA2432500A1 Novel therapeutic use of a thienylcyclohexylamine derivative |
| 06/27/2002 | CA2432417A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 06/27/2002 | CA2432315A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | CA2432310A1 Electrically responsive promoter system |
| 06/27/2002 | CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | CA2432066A1 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders |
| 06/27/2002 | CA2431965A1 Novel substituted imidazotriazinones as pde ii-inhibitors |
| 06/27/2002 | CA2431891A1 Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | CA2431592A1 Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors |
| 06/27/2002 | CA2431278A1 Use of triaminobenzene derivatives for treatment of anxiety disorders |
| 06/27/2002 | CA2431139A1 Oxidoreductases |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect |
| 06/26/2002 | EP1216996A2 Method to synthesise biphenylyl derivatives |
| 06/26/2002 | EP1216707A1 New therapeutic uses of a SMR-1-peptide |
| 06/26/2002 | EP1216704A1 Controlled release valproate composition |
| 06/26/2002 | EP1216703A2 Thiocarbamate sulfoxide composition for deterring ethanol ingestion |
| 06/26/2002 | EP1216309A2 Methods for targeting rna molecules |
| 06/26/2002 | EP1216300A1 Methods and compositions relating to sodium channel beta1a subunits |
| 06/26/2002 | EP1216297A2 Double transgenic animals as models for neurodegenerative disease |
| 06/26/2002 | EP1216258A1 Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| 06/26/2002 | EP1216257A1 Compounds for the treatment of ischemia |
| 06/26/2002 | EP1216250A1 Thienoisoxazolyl and thienylpyrrazolyl phenoxy substituted propyl derivatives useful as d4 antagonists |
| 06/26/2002 | EP1216249A2 Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists |
| 06/26/2002 | EP1216248A2 Triazolopyrimidine derivatives |
| 06/26/2002 | EP1216246A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 06/26/2002 | EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 06/26/2002 | EP1216244A1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d 4? antagonists |
| 06/26/2002 | EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216240A1 Amide compounds |
| 06/26/2002 | EP1216239A1 Piperazine derivatives as 5-ht1b antagonists |
| 06/26/2002 | EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216232A1 Heterocyclic compounds and methods for modulating cxcr3 function |
| 06/26/2002 | EP1216221A2 Rxr modulators with improved pharmacologic profile |
| 06/26/2002 | EP1216047A2 Novel combination of loteprednol and beta2-adrenoceptor agonists |
| 06/26/2002 | EP1216044A1 Compositions having improved stability |
| 06/26/2002 | EP1216043A1 Retard form containing alpha-lipoic acid (derivatives) |
| 06/26/2002 | EP1216032A1 Oral controlled release formulations |
| 06/26/2002 | EP1216031A2 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 06/26/2002 | EP1216026A1 Compositions of tocol-soluble therapeutics |
| 06/26/2002 | EP1216024A1 Formulation for menopausal women |